mirtazapine has been researched along with Multiple Sclerosis, Relapsing-Remitting in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Damasceno, A | 1 |
| von Glehn, F | 1 |
| Martinez, AR | 1 |
| Longhini, AL | 1 |
| Deus-Silva, L | 1 |
| Brandão, CO | 1 |
| Santos, LM | 1 |
| Damasceno, BP | 1 |
1 other study available for mirtazapine and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Topics: Antibodies, Monoclonal, Humanized; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressiv | 2011 |